GM-CSF can cause T cell activation; results of sequential chemo-immunotherapy.
Groenewegen
G
G
Department of Internal Medicine and Oncology, University Hospital Utrecht, The Netherlands. g.groenewegen@digd.azu.nl
de Gast
G C
GC
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D016130:Immunophenotyping; D008213:Lymphocyte Activation; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000187:drug effects*
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor